Edward M. Wolin

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors”.

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

New England Journal of Medicine(2024)10.1056/nejmoa2403991

N/A

3.0DataRank · unranked

141 citations

Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, Sydney Pulsipher +19 more

LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

Annals of Oncology(2023)10.1016/j.annonc.2023.10.047

N/A

0.500DataRank · unranked

27 citations

Susan M. Geyer, F-S. Ou, Michael V. Knopp, Spencer C. Behr, Tyler Zemla +14 more

1712P Efficacy and safety of cabozantinib (CABO) for advanced lung and thymic neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of phase III CABINET Trial (Alliance A021602)

Annals of Oncology(2025)10.1016/j.annonc.2025.08.2340

N/A

0DataRank · unranked

1 citations

T. Zemla, Susan M. Geyer, Jonathan Strosberg, Þorvarður R. Hálfdánarson, Nikolaos A. Trikalinos +13 more